A placebo-controlled study of pyritinol in dementia.

Cooper AJ, Magnus RV.

Pharmatherapeutica 1980;2(5):317-22

ABSTRACT

A double-blind, placebo-controlled trial was carried out on 40 patients suffering from moderately advanced dementia. The patients were allocated randomly either pyritinol (800 mg daily) or identical placebo for 3 months. Assessments using a modified Crichton Geriatric Behavioural Rating Scale were made pre-treatment and monthly up to 3 months, and then at follow-up at 6 months. Patients on pyritinol showed significantly higher levels of improvement than did those on placebo. Laboratory tests conducted throughout remained within normal limits for both groups

HOME              to order

1.  Pyritinol on the clinical course of traumatic coma
2.  Effect of pyritinol on sequelae of head injuries.
3.  Pyritinol in the treatment of rheumatoid arthritis
4.  Psychopharmacological effects of Pyritinol
5.  Pyritinol as a free radical scavenger
6.  Pyritinol's effect on brain blood flow in dementia patients
7.  Stimulation of neutrophil functions by Pyritinol
8.  Pyritinol's effect on senile dementia of the Alzheimer type
9.  Pyritinol's effect on advanced dementia